Gyre Therapeutics, Inc. (NASDAQ: GYRE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.20 | Insider Own | - | Shs Outstand | 111.49M | Perf Week | 6.53% |
| Market Cap | 800.49M | Forward P/E | - | EPS next Y | -0.23 | Insider Trans | -0.18% | Shs Float | 32.86M | Perf Month | 2.87% |
| Enterprise Value | 727.49M | PEG | - | EPS next Q | -0.15 | Inst Own | - | Short Float | 1.53% | Perf Quarter | 18.09% |
| Income | -18.00M | P/S | 6.67 | EPS this Y | -100.00% | Inst Trans | - | Short Ratio | 21.36 | Perf Half Y | 2.43% |
| Sales | 120.00M | P/B | 4.85 | EPS next Y | 41.25% | ROA | -8.70% | Short Interest | 1.71M | Perf YTD | 1.70% |
| Book/sh | 1.48 | P/C | 10.67 | EPS next 5Y | - | ROE | -15.77% | 52W High | 9.42 -23.78% | Perf Year | -5.40% |
| Cash/sh | 0.67 | P/FCF | - | EPS past 3/5Y | -9.14% - | ROIC | -9.69% | 52W Low | 5.44 31.99% | Perf 3Y | -0.28% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 4.68% 40.99% | Gross Margin | 94.30% | Volatility | 4.47% 4.29% | Perf 5Y | -89.07% |
| Dividend TTM | - | EV/Sales | 6.06 | EPS Y/Y TTM | -500.00% | Oper. Margin | -13.97% | ATR (14) | 0.31 | Perf 10Y | -97.23% |
| Dividend Ex-Date | Jan 13, 2023 | Quick Ratio | 3.86 | Sales Y/Y TTM | 13.21% | Profit Margin | -14.52% | RSI (14) | 62.09 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.26 | EPS Q/Q | - | SMA20 | 6.75% | Beta | 2.32 | Target Price | 17.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | -3.33% | SMA50 | 10.63% | Rel Volume | 1.75 | Prev Close | 6.70 |
| Employees | 625 | LT Debt/Eq | 0.01 | Earnings | Nov 06 | SMA200 | 1.01% | Avg Volume | 81.93K | Price | 7.18 |
| IPO Date | Apr 12, 2006 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -111.76% 9.87% | Net Debt/EBITDA | 2.84 | Volume | 143,213 | Change | 7.16% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-10-25 | Initiated | Jefferies | Buy | $16 |
| Aug-26-25 | Initiated | H.C | Buy | $18 |
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 120 | 117 | 106 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 7 | 5 | 4 | — | — | — | — | — | — | |
| Gross Profit | 112 | 111 | 102 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 94 | 86 | 74 | — | — | — | — | — | — | |
| Research and Development | 33 | 14 | 12 | — | — | — | — | — | — | |
| Other Operating Expense | 2 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -16 | 11 | 16 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1 | 3 | 7 | — | — | — | — | — | — | |
| Net Income Before Taxes | -15 | 14 | 23 | — | — | — | — | — | — | |
| Income Taxes | 2 | 5 | 5 | — | — | — | — | — | — | |
| Consolidated Net Income | -18 | 5 | 12 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -18 | 10 | 18 | — | — | — | — | — | — | |
| Net Income | -18 | 5 | 12 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.20 | 0.06 | 0.14 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.20 | 0.06 | 0.14 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.20 | 0.02 | 0.05 | — | — | — | — | — | — | |
| EBITDA | -14 | 17 | 18 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 313.78 | 242.00 | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.04 | 5.37 | 9.70 | — | — | — | — | — | — | |
| Gross Margin | 93.33 | 94.87 | 96.23 | — | — | — | — | — | — | |
| Operating Margin | -13.33 | 9.40 | 15.09 | — | — | — | — | — | — | |
| Net Margin | -15.00 | 4.27 | 11.32 | — | — | — | — | — | — | |
| Shares Outstanding | 101 | 89 | 85 | — | — | — | — | — | — | |
| Market Capitalization | 725 | 628 | 1,029 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ye Weiguo | Chief Operating Officer | Jun 18 '26 | Sale | 6.35 | 3,000 | 19,050 | 700,000 | Jun 22 |
| Ye Weiguo | Chief Operating Officer | Jun 18 '26 | Option Exercise | 0.75 | 3,000 | 2,250 | 703,000 | Jun 22 |
| Ye Weiguo | Chief Operating Officer | Jun 10 '26 | Option Exercise | 0.75 | 11,418 | 8,564 | 706,418 | Jun 22 |
| Ye Weiguo | Chief Operating Officer | Jun 10 '26 | Sale | 6.22 | 11,418 | 71,056 | 700,000 | Jun 22 |
| Ye Weiguo | Chief Operating Officer | Jun 09 '26 | Sale | 6.14 | 17,500 | 107,480 | 700,000 | Jun 22 |
| Ye Weiguo | Chief Operating Officer | Jun 09 '26 | Option Exercise | 0.75 | 17,500 | 13,125 | 835,701 | Jun 22 |
| Ye Weiguo | Chief Operating Officer | Jun 11 '26 | Option Exercise | 0.75 | 2,800 | 2,100 | 702,800 | Jun 15 |
| Ye Weiguo | Chief Operating Officer | Jun 11 '26 | Sale | 6.17 | 2,800 | 17,276 | 700,000 | Jun 15 |
| Ye Weiguo | Chief Operating Officer | Jun 05 '26 | Option Exercise | 0.75 | 15,401 | 11,551 | 715,401 | Jun 08 |
| Ye Weiguo | Chief Operating Officer | Jun 05 '26 | Sale | 6.40 | 15,401 | 98,566 | 700,000 | Jun 08 |
| Ye Weiguo | Chief Operating Officer | Jun 04 '26 | Option Exercise | 0.75 | 19,575 | 14,681 | 719,575 | Jun 08 |
| Ye Weiguo | Chief Operating Officer | Jun 04 '26 | Sale | 6.13 | 19,575 | 119,995 | 700,000 | Jun 08 |
| Ye Weiguo | Chief Operating Officer | May 26 '26 | Option Exercise | 0.75 | 4,000 | 3,000 | 704,000 | May 27 |
| Ye Weiguo | Chief Operating Officer | May 26 '26 | Sale | 6.10 | 4,000 | 24,400 | 700,000 | May 27 |
| Ye Weiguo | Chief Operating Officer | May 22 '26 | Option Exercise | 0.75 | 3,500 | 2,625 | 703,500 | May 27 |